Trials / Completed
CompletedNCT01431898
Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection
A Phase 1b, Randomized, Single-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 82 (actual)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a research study to evaluate the safety, tolerability and anti-viral activity of GS-9669 in patients with Hepatitis C infection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GS-9669 tablets | |
| DRUG | Placebo to Match GS-9669 tablet |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2011-12-01
- Completion
- 2012-05-01
- First posted
- 2011-09-12
- Last updated
- 2012-07-25
Locations
11 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT01431898. Inclusion in this directory is not an endorsement.